Long idea

2020년 11월 24일

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company’s products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, and other kinases implicated in growth and spread of cancer. It has collaboration and license agreement with Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., Roche, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Merck, Daiichi Sankyo Company, Limited, and clinical collaboration with Ipsen. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.

Market Cap
$
5.7B
Dividend Yield
Beta vs SPX
0.9
Short Interest
4.6%
Volatility (1Y)
45.4
Hedge Fund Held
Industry
Biotechnology
Competitors
ABBV
AMGN
GILD
VRTX
Performance
14.46
Low
18.39
1-Year Price Range
27.42
High
1M
3M
YTD
1Y
EXEL
-15.8%
-17.3%
4.4%
13.0%
EXEL vs SPX
-19.5%
-23.1%
-8.3%
-4.2%
Valuation
Forward P/E (NTM)
109.9X
Trailing P/E (LTM)
38.4X
Price/Book
3.1X
EV/Sales (LTM)
4.8X
EV/EBITDA (LTM)
25.4X
Capital Structure
Market Cap
$
5.7B
Total Debt
$
48.3M
Cash
$
1.2B
Other
Enterprise Value
$
4.6B
Earnings Estimates
Fiscal Year
EPS
YoY
Sales
YoY
2020
0.46
-54.6%
$
930.7M
-3.8%
2021
0.82
77.4%
$
1.2B
24.5%
2022
1.48
80.5%
$
1.5B
33.4%

2021년 1월 13일

거래청산: 타겟 닿음

Done!